Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Predictive Utility of the Dimethylarginines and Ischemia Modified Albumin as Prognostic Biomarkers in Patients With Acute-on-chronic Liver Failure

NCT01071746 is registered in ClinicalTrials.gov with University College London Hospitals as lead sponsor.

NCT NCT01071746
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01071746 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Predictive Utility of the Dimethylarginines and Ischemia Modified Albumin as Prognostic Biomarkers in Patients With Acute-on-chronic Liver Failure
Lead sponsor
University College London Hospitals
Phase
Observational
Overall status
Unknown status
Start date
September 30, 2008
Completion date
November 30, 2010
Enrollment
700 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

liver cirrhosis